An open label pilot study of Zoledronate (Aclasta 5mg iv) in the treatment of Ankylosing Spondylitis.

Trial Profile

An open label pilot study of Zoledronate (Aclasta 5mg iv) in the treatment of Ankylosing Spondylitis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2014

At a glance

  • Drugs Zoledronic acid (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2014 Results presented at the 36th Annual Meeting of the American Society for Bone and Mineral Research.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top